Hepatic Manifestations in Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome. Journal of Rheumatology. 2026.
The Renal Activity Index for Lupus: Validation for Prediction of Kidney Inflammation in Adult Patients With Lupus Nephritis. Journal of Rheumatology. 2026; 53(3):283-291.
Potential role for immune cell signatures as predictors of acute and chronic pain in adolescents post major musculoskeletal surgery. Brain, Behavior, and Immunity. 2026; 131:106133.
Cyt-Geist: Current and Future Challenges in Cytometry: Reports of the CYTO 2025 Conference Workshops. Cytometry. Part A : the journal of the International Society for Analytical Cytology. 2026; 109(1):5-41.
Validation of the Pediatric Arthritis Ultrasound Scoring System for the Elbow, Wrist, and Finger Joints in Children With Juvenile Idiopathic Arthritis. Arthritis Care and Research. 2025.
Utility of patient-reported outcomes for pulmonary symptoms and sleep disturbance and impairment in children with systemic juvenile idiopathic arthritis. Pediatric Rheumatology. 2025; 23(1):74.
Clinical, Immunologic, and Genetic Characteristics in Patients With Syndrome of Undifferentiated Recurrent Fevers. Arthritis & Rheumatology. 2025; 77(5):596-605.
Experience with T Cell–Depleted Allogeneic HSCT for Refractory sJIA Associated with Lung Disease. Journal of Human Immunity. 2025; 1(CIS2025).
Allogeneic haematopoietic stem-cell transplantation for children with refractory systemic juvenile idiopathic arthritis and associated lung disease: outcomes from an international, retrospective cohort study. The Lancet Rheumatology. 2025; 7(4):e243-e251.
Lack of HLH in FMF. Pediatric Rheumatology. 2025; 23(1):14.
Achieving Medication-Free Remission in Patients With Juvenile Dermatomyositis. ACR Open Rheumatology. 2025; 7(1):e11751.
Current treatment in macrophage activation syndrome worldwide: a systematic literature review to inform the METAPHOR project. Rheumatology. 2025; 64(1):32-44.
Automated descriptive cell type naming in flow and mass cytometry with CytoPheno. Scientific Reports. 2025; 15(1):26750.
Development and Validation of Multiplex Assays for Lupus Nephritis Activity Biomarkers. Kidney International Reports. 2025; 10(7):2255-2264.
POS0295 RELATIONSHIP AMONG A PEDIATRIC-SPECIFIC ULTRASOUND SCORING SYSTEM FOR THE EVALUATION OF ARTHRITIS AND BIOLOGIC MARKERS OF INFLAMMATION. Annals of the Rheumatic Diseases. 2025; 84:556.
Candidate Tear-Based Uveitis Biomarkers in Children with JIA Based on Arthritis Activity and Topical Corticosteroid Use. Ocular Immunology and Inflammation. 2025; 33(4):603-612.
Baseline Clinical Features and Biomarker Profiles of the Childhood Arthritis and Rheumatology Research Alliance Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease Cohort. Arthritis Care and Research. 2025.
Transcriptional Profiling of Tofacitinib Treatment in Juvenile Idiopathic Arthritis: Implications for Treatment Response Prediction. Arthritis Care and Research. 2025; 77(4):513-521.
EULAR/PReS recommendations for the diagnosis and management of Still's disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still's disease. Annals of the Rheumatic Diseases. 2024; 83(12):1614-1627.
Enrichment of Rare Variants of Hemophagocytic Lymphohistiocytosis Genes in Systemic Juvenile Idiopathic Arthritis. Arthritis & Rheumatology. 2024; 76(10):1566-1572.
Safety and effectiveness of abatacept in juvenile idiopathic arthritis: results from the PRINTO/PRCSG registry. Rheumatology. 2024; 63(SI2):SI195-SI206.
Disease Course, Treatments, and Outcomes of Children With Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease. Arthritis Care and Research. 2024; 76(3):328-339.
Atherosclerosis Progression in the APPLE Trial Can Be Predicted in Young People With Juvenile-Onset Systemic Lupus Erythematosus Using a Novel Lipid Metabolomic Signature. Arthritis & Rheumatology. 2024; 76(3):455-468.
The 4th NextGen therapies for SJIA and MAS: part 2 phenotypes of refractory SJIA and the landscape for clinical trials in refractory SJIA. Pediatric Rheumatology. 2024; 21(Suppl 1):87.
Part 5: Allogeneic HSCT in refractory SJIA with lung disease; recent cases from centers in North America & Europe. Pediatric Rheumatology. 2024; 21(Suppl 1):86.
Proceedings from the 4th NextGen Therapies for SJIA and MAS virtual symposium held February 13-14, 2022. Pediatric Rheumatology. 2024; 21(Suppl 1):91.
The 4th NextGen therapies for SJIA and MAS: part 3 clinical trials in refractory SJIA: historic controls as an alternative to a withdrawal design study. Pediatric Rheumatology. 2024; 21(Suppl 1):150.
Recombinant Interleukin-1 Receptor Antagonist Is an Effective First-Line Treatment Strategy in New-Onset Systemic Juvenile Idiopathic Arthritis, Irrespective of HLA-DRB1 Background and IL1RN Variants. Arthritis & Rheumatology. 2024; 76(1):119-129.
Genetics of Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis. Advances in Experimental Medicine and Biology. 2024; 1448:121-126.
Diagnostic Accuracy Study of the Pediatric-Specific Ultrasound Scoring System for the Knee Joint in Children With Juvenile Idiopathic Arthritis. Arthritis Care and Research. 2024; 76(2):251-258.
Biomarker Changes in Response to Tofacitinib Treatment in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis. Arthritis Care and Research. 2024; 76(12):1723-1732.
S100 proteins as potential predictive biomarkers of abatacept response in polyarticular juvenile idiopathic arthritis. Arthritis Research & Therapy. 2024; 26(1):125.
Population-level single-cell genomics reveals conserved gene programs in systemic juvenile idiopathic arthritis. Journal of Clinical Investigation. 2023; 133(22).
Diagnosis and Management of the Systemic Juvenile Idiopathic Arthritis Patient with Emerging Lung Disease. Paediatric Drugs. 2023; 25(6):649-658.
The 2022 EULAR/ACR points to consider at the early stages of diagnosis and management of suspected haemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS). Annals of the Rheumatic Diseases. 2023; 82(10):1271-1285.
The 2022 EULAR/ACR Points to Consider at the Early Stages of Diagnosis and Management of Suspected Haemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLH/MAS). Arthritis & Rheumatology. 2023; 75(10):1714-1732.
Efficacy and safety of emapalumab in macrophage activation syndrome. Annals of the Rheumatic Diseases. 2023; 82(6):857-865.
OP0166 LONG-TERM FOLLOW-UP OF PATIENTS ADMINISTERED EMAPALUMAB, AN ANTI–INTERFERON-Γ MONOCLONAL ANTIBODY, TO TREAT MACROPHAGE ACTIVATION SYNDROME (MAS) SECONDARY TO SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA) Annals of the Rheumatic Diseases. 2023; 82:110-111.
Lung Ultrasound in Children With Systemic Juvenile Idiopathic Arthritis-Associated Interstitial Lung Disease. Arthritis Care and Research. 2023; 75(5):983-988.
Alternative Biologic Therapy in Children Failing Conventional TNFα Inhibitors for Refractory, Noninfectious, Chronic Anterior Uveitis. American Journal of Ophthalmology. 2022; 244:183-195.
Identification of Distinct Inflammatory Programs and Biomarkers in Systemic Juvenile Idiopathic Arthritis and Related Lung Disease by Serum Proteome Analysis. Arthritis & Rheumatology. 2022; 74(7):1271-1283.
International Consensus for the Dosing of Corticosteroids in Childhood-Onset Systemic Lupus Erythematosus With Proliferative Lupus Nephritis. Arthritis & Rheumatology. 2022; 74(2):263-273.
Reasons for Initiating Canakinumab among Patients with Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still's Disease in the U.S. Real-World Settings. Rheumatology and Therapy. 2022; 9(1):265-283.
Implementing Research Shared (Core) Facility Billing Systems. Journal of Biomolecular Techniques. 2022; 33(4).
Establishing a biosafety plan for a flow cytometry shared resource laboratory. Cytometry. Part A : the journal of the International Society for Analytical Cytology. 2022; 101(5):380-386.